Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Appointment of new Chief Executive Officer

28 May 2021

Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that Greg Madison has been appointed as Chief Executive Officer (CEO) with effect from Tuesday, 1 June 2021.

Greg has an excellent commercialisation track record and, in particular, he has deep knowledge and previous experience in the US iron deficiency marketplace.

For full details click here.

Back to news